WO2024134596 - ADIPONECTIN ALONE OR IN COMBINATION WITH EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR IMMUNE RELATED ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS
National phase entry is expected:
Publication Number
WO/2024/134596
Publication Date
27.06.2024
International Application No.
PCT/IB2023/063139
International Filing Date
21.12.2023
Title **
[English]
ADIPONECTIN ALONE OR IN COMBINATION WITH EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR IMMUNE RELATED ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS
[French]
ADIPONECTINE SEULE OU EN COMBINAISON AVEC UNE PHOTOPHÉRÈSE EXTRACORPORELLE (PEC) POUR ÉVÉNEMENTS INDÉSIRABLES D'ORIGINE IMMUNOLOGIQUE, D'INHIBITEURS DE POINTS DE CONTRÔLE IMMUNITAIRE
Applicants **
MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Inventors
ZEISER, Robert
Priority Data
22215382.7
21.12.2022
EP
63/517,685
04.08.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3942 | |
| EPO | Filing, Examination, Granting | 17814 | |
| Japan | Filing, Examination, Granting | 2338 | |
| South Korea | Filing, Examination, Granting | 2481 | |
| USA | Filing, Examination, Granting | 6740 |
Total:
33,315
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The disclosure relates to a substance adiponectin and/or adiponectin receptor agonist (ARA) for use in the treatment of immune checkpoint blockade (ICB)-induced immune related adverse events (irAEs) in a subject, wherein the subject is preferably receiving checkpoint blockade therapy as a cancer therapy. As well as to a combination medication comprising adiponectin and/or adiponectin receptor agonist (ARA) and a photosensitizing agent for combined use in the treatment of immune checkpoint blockade (ICB)-induced immune related adverse events (irAEs) in a subject, wherein the treatment further comprises the extracorporeal irradiation of a blood sample of the subject with ultraviolet A (UVA), preferably extracorporeal photopheresis (ECP) therapy.[French]
Est divulguée une substance adiponectine et/ou un agoniste de récepteur de l'adiponectine (ARA) destiné(s) à servir dans le traitement d'événements indésirables d'origine immunologique (irAEs) induits par blocage de points de contrôle immunitaire (ICB) chez un individu, ce dernier recevant de préférence un traitement de blocage des points de contrôle comme traitement anticancéreux. Est également divulgué un médicament combiné comprenant de l'adiponectine et/ou un agoniste du récepteur de l'adiponectine (ARA) et un agent photosensibilisant pour une utilisation combinée dans le traitement d'événements indésirables d'origine immunologique (irAEs) induits par blocage de points de contrôle immunitaire (ICB) chez un individu, le traitement consistant également à réaliser une irradiation extracorporelle d'un échantillon sanguin de l'individu avec des ultraviolets A (UVA), de préférence un traitement par photophérèse extracorporelle (PEC).